PARTNER I2016-11-29T15:55:41+00:00

PARTNER I

CARDIOLOGY

Definition A study which asked if transcatheter aortic valve replacement—TAVR in patients with severe, inoperable aortic stenosis yielded a sustained mortality benefit, improved functional status and a decreased rate of rehospitalization vs. standard therapy*.

*Which frequently consisted of balloon valvuloplasty

Conclusion Yes. 5-year all-cause mortality was 94% with standard therapy and 72% in the TAVR group (P<.0001). The standard therapy group had a median survival of 11 months vs. 29 months in the TAVR group (P<.001). 

Reference http://www.healio.com/cardiology/intervention/news/online/%7Beeed3586-b54b-41be-909d-6edea73cd1ae%7D/partner-i-tavr-delivers-mortality-benefit-decreases-rehospitalization-at-5-years

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.